Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 48.39%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.44 per share when it actually produced a loss of $0.30, delivering a surprise of 31.82%.Over the last four quarter ...